DRAFT

INTERACTION PROFILE FOR:
CHLOROFORM, 1,1-DICHLOROETHYLENE,
TRICHLOROETHYLENE, AND VINYL CHLORIDE

U.S. Department of Health and Human Services
Public Health Service
Agency for Toxic Substances and Disease Registry

August 2007
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) mandate that the Agency for Toxic Substances and Disease Registry (ATSDR) shall assess whether adequate information on health effects is available for the priority hazardous substances. Where such information is not available or under development, ATSDR shall, in cooperation with the National Toxicology Program (NTP), initiate a program of research to determine these health effects. The Act further directs that where feasible, ATSDR shall develop methods to determine the health effects of substances in combination with other substances with which they are commonly found.

To carry out these legislative mandates, ATSDR’s Division of Toxicology and Environmental Medicine (DTEM) has developed and coordinated a mixtures program that includes trend analysis to identify the mixtures most often found in environmental media, in vivo and in vitro toxicological testing of mixtures, quantitative modeling of joint action, and methodological development for assessment of joint toxicity. These efforts are interrelated. For example, the trend analysis suggests mixtures of concern for which assessments need to be conducted. If data are not available, further research is recommended. The data thus generated often contribute to the design, calibration, or validation of the methodology. This pragmatic approach allows identification of pertinent issues and their resolution as well as enhancement of our understanding of the mechanisms of joint toxic action. All the information obtained is thus used to enhance existing or developing methods to assess the joint toxic action of environmental chemicals. Over a number of years, ATSDR scientists in collaboration with mixtures risk assessors and laboratory scientists have developed approaches for the assessment of the joint toxic action of chemical mixtures. As part of the mixtures program a series of documents, Interaction Profiles, are being developed for certain priority mixtures that are of special concern to ATSDR.

The purpose of an Interaction Profile is to evaluate data on the toxicology of the “whole” priority mixture (if available) and on the joint toxic action of the chemicals in the mixture in order to recommend approaches for the exposure-based assessment of the potential hazard to public health. Joint toxic action includes additivity and interactions. A weight-of-evidence approach is commonly used in these documents to evaluate the influence of interactions in the overall toxicity of the mixture. The weight-of-evidence evaluations are qualitative in nature, although ATSDR recognizes that observations of toxicological interactions depend greatly on exposure doses and that some interactions appear to have thresholds. Thus, the interactions are evaluated in a qualitative manner to provide a sense of what influence the interactions may have when they do occur.
CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHORS:

Hana Pohl, M.D., Ph.D.
ATSDR, Division of Toxicology and Environmental Medicine, Atlanta, GA

Mark Osier, Ph.D., D.A.B.T.
Syracuse Research Corporation, Syracuse, NY

Joan Colman, Ph.D.
Syracuse Research Corporation, Syracuse, NY

***DRAFT—DO NOT CITE OR QUOTE—***
PEER REVIEW

A peer review panel was assembled for this profile. The panel consisted of the following members:

1. Richard Hertzberg, Ph.D., Waste Management Division, U.S. Environmental Protection Agency, Atlanta, GA, USA /currently retired/
2. Kannan Krishnan, Ph.D., Human Toxicology Research Group, University of Montreal, Montreal, PQ, Canada
3. Scott Masten, Ph.D., Environmental Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA

All reviewers were selected in conformity with the conditions for peer review specified in CERCLA Section 104(I)(13).

Scientists from ATSDR have reviewed the peer reviewers’ comments and determined which comments will be included in the profile. A listing of the peer reviewers’ comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this mixture. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile’s final content. The responsibility for the content of this profile lies with the ATSDR.
SUMMARY

Chloroform, 1,1-dichloroethylene, trichloroethylene, and vinyl chloride were chosen as the subject mixture for this profile because they frequently occur in water around hazardous waste sites. The primary routes of exposure of nearby populations to mixtures of these volatile chemicals are likely to be inhalation and oral, and the durations of concern are intermediate and chronic. ATSDR toxicological profiles are available for all four of the components of the mixture (ATSDR 1994, 1997a, 1997b, 2004b); these documents are the primary sources of information presented in the Appendices concerning the toxicokinetics, health effects, mechanisms of action, and health guidelines for these chemicals.

The purposes of this profile are to: (1) evaluate data (if available) on health hazards, and their dose-response relationships, from exposure to this four-component mixture; (2) evaluate data on the joint toxic actions of components of this mixture; and (3) make recommendations for exposure-based assessments of the potential impact of joint toxic action of the mixture on public health.

No studies were located that examined health effects in humans or animals exposed to mixtures exclusively containing chloroform, 1,1-dichloroethylene, trichloroethylene, and vinyl chloride, and no physiologically-based pharmacokinetic/pharmacodynamic (PBPK/PD) models for this mixture have been developed. A component-based approach (ATSDR 2001, 2004a) was applied, wherein the potential influence of individual components on the toxicity of other components in the mixture is evaluated. As joint action data are lacking for three of the six-component pairs, the mechanisms of action for each component pair were also analyzed for evidence of potential joint toxic actions. The weight-of-evidence analysis indicated that the most likely mode of joint action for the individual component pairs was competition for cytochrome P450 2E1 (CYP2E1) active sites, but only at high exposure levels where metabolic saturation may occur. Competitive inhibition of metabolism was predicted to result in less-than-additive toxicity for effects mediated through the generation of reactive metabolites (e.g., hepatic, renal, and carcinogenic effects), greater-than-additive toxicity for effects due to the toxicity of the parent compound (neurological effects of chloroform), and uncertain results for effects that may be due to both parent compound and metabolite (neurological effects of trichloroethylene). Some evidence was available from acute co-exposure studies in animals to support these predictions for hepatic effects.

Component-based approaches that assume endpoint-specific additive joint toxic action are recommended for exposure-based assessments of possible noncancer or cancer health hazards from inhalation exposure to chloroform, 1,1-dichloroethylene, trichloroethylene, and vinyl chloride, because there are no direct data available to characterize health hazards (and dose-response relationships) from the four-component
mixture. The weight-of-evidence analysis predicted nonadditive joint action at high exposure levels, but the mode of action (competitive inhibition of metabolism at saturating exposure levels) is not relevant to lower exposure scenarios, as would occur from exposures from water near hazardous waste sites; thus, the additivity assumption appears to be suitable in the interest of protecting public health.

The health effects or endpoints of concern for this mixture are hepatic, renal, and developmental effects (all four chemicals), immunological (chloroform, trichloroethylene, vinyl chloride), neurological (chloroform, trichloroethylene), and cancer (chloroform, trichloroethylene, vinyl chloride). To screen this mixture for potential hazards to public health using the additivity approach, endpoint-specific hazard indexes are estimated using Minimal Risk Levels (MRLs) and target-organ toxicity doses (TTDs, derived in this interaction profile) for the exposure routes and durations of concern. This approach is appropriate when the hazard quotients for two or more of the mixture components equal or exceed 0.1. Endpoint-specific hazard indexes (e.g., hazard indexes for hepatic effects) for the same exposure duration (e.g., chronic) can be summed across routes (inhalation and oral) to estimate the aggregate hazard, if it is likely that the same individual or group of individuals would be exposed by both routes. The total cancer risk is estimated by summing the cancer risks for chloroform and vinyl chloride (no unit risk or potency factor is available to estimate risk from trichloroethylene). Cancer risks for the same exposure duration can be summed across routes if it is likely that the same individual or group of individuals would be exposed by both routes. If an endpoint-specific hazard index exceeds one, or the sum of the cancer risks for these chemicals equals or exceeds $1 \times 10^{-4}$, then further evaluation is needed (ATSDR 2004a), using biomedical judgment and community-specific health outcome data, and taking into account community health concerns (ATSDR 1992). If exposures levels are very high (100-fold or more above the MRLs or TTDs), interactions may occur, and their impact on the hazard indexes and cancer risks can be estimated using the weight-of-evidence predictions discussed earlier in this summary.

***DRAFT—DO NOT CITE OR QUOTE***
# TABLE OF CONTENTS

CONTRIBUTORS ........................................................................................................................................... v
PEER REVIEW ............................................................................................................................................. vii
SUMMARY ....................................................................................................................................................... ix
TABLE OF CONTENTS ................................................................................................................................. xi
LIST OF TABLES ........................................................................................................................................... xiii
LIST OF ACRONYMS, ABBREVIATIONS, AND SYMBOLS ........................................................................ xvi
1. INTRODUCTION .......................................................................................................................................... 1
2. JOINT TOXIC ACTION DATA FOR THE MIXTURE OF CONCERN AND COMPONENT MIXTURES ................................................................................................................................. 5
  2.1 Mixture of Concern .................................................................................................................................. 5
  2.2 Component Mixtures ............................................................................................................................. 5
    2.2.1 Chloroform and 1,1-Dichloroethylene ............................................................................................ 5
    2.2.2 Chloroform and Trichloroethylene ............................................................................................... 6
    2.2.3 Chloroform and Vinyl Chloride ................................................................................................... 9
    2.2.4 1,1-Dichloroethylene and Trichloroethylene ............................................................................... 9
    2.2.5 1,1-Dichloroethylene and Vinyl Chloride .................................................................................... 11
    2.2.6 Trichloroethylene and Vinyl Chloride .......................................................................................... 13
  2.3 Relevance of the Joint Toxic Action Data and Approaches to Public Health ........................................ 14
  2.4 Recommendations for Data Needs ....................................................................................................... 29
3. RECOMMENDATION FOR EXPOSURE-BASED ASSESSMENT OF JOINT TOXIC ACTION OF THE MIXTURE ........................................................................................................................................ 31
4. CONCLUSIONS ............................................................................................................................................ 39
5. REFERENCES ................................................................................................................................................ 41
APPENDIX A: BACKGROUND INFORMATION FOR CHLOROFORM ........................................................................... 43
  A.1 Toxicokinetics ....................................................................................................................................... 43
  A.2 Health Effects ....................................................................................................................................... 45
  A.3 Mechanisms of Action ......................................................................................................................... 49
  A.4 Health Guidelines ............................................................................................................................... 49
  A.5 Derivation of Target-Organ Toxicity Dose (TTD) Values .................................................................... 51
  A.6 References ............................................................................................................................................. 57
APPENDIX B: BACKGROUND INFORMATION FOR 1,1-DICHLOROETHYLENE ................................................................... 65
  B.1 Toxicokinetics ....................................................................................................................................... 65
  B.2 Health Effects ....................................................................................................................................... 66
  B.3 Mechanisms of Action ......................................................................................................................... 69
  B.4 Health Guidelines ................................................................................................................................ 69
  B.5 Derivation of Target-Organ Toxicity Dose (TTD) Values .................................................................... 71
  B.6 References ............................................................................................................................................. 75
APPENDIX C: BACKGROUND INFORMATION FOR TRICHLOROETHYLENE ..................................................................... 81
  C.1 Toxicokinetics ....................................................................................................................................... 81
  C.2 Health Effects ....................................................................................................................................... 83
  C.3 Mechanisms of Action ......................................................................................................................... 84
  C.4 Health Guidelines ............................................................................................................................... 85
  C.5 Derivation of Target Organ Toxicity Dose (TTD) Values ................................................................. 86
  C.6 References ............................................................................................................................................. 93
APPENDIX D: BACKGROUND INFORMATION FOR VINYL CHLORIDE .................................................................... 97
  D.1 Toxicokinetics ....................................................................................................................................... 97
  D.2 Health Effects ....................................................................................................................................... 98

***DRAFT—DO NOT CITE OR QUOTE—***
LIST OF TABLES

Table 1. Potential Health Effects of Concern for Intermediate and Chronic Inhalation and Oral Exposure to the Mixture Chloroform, 1,1-Dichloroethylene, Trichloroethylene, and Vinyl Chloride................. 4
Table 2. Summary of Available Data on the Joint Effects of Simultaneous Exposure to Chloroform and 1,1-Dichloroethylene and Trichloroethylene ................................................................................. 9
Table 3. Summary of Available Data on the Joint Effects of Simultaneous Exposure to 1,1-Dichloroethylene and Trichloroethylene .......................................................................................................... 11
Table 4. Summary of Available Data on the Joint Effects of Simultaneous and Sequential Exposure to 1,1-Dichloroethylene and Vinyl Chloride............................................................................................................................ 12
Table 5. Summary of Available Data on the Joint Effects of Simultaneous Exposure to Trichloroethylene and Vinyl Chloride............................................................................................................. ................. 13
Table 6. Binary Weight-of-Evidence Scheme for the Assessment of Chemical Interactions .................... 16
Table 7. Effect of Chloroform on 1,1-Dichloroethylene ............................................................................ 17
Table 8. Effect of 1,1-Dichloroethylene on Chloroform ............................................................................ 18
Table 9. Effect of Chloroform on Trichloroethylene ................................................................................. 19
Table 10. Effect of Trichloroethylene on Chloroform ............................................................................. 20
Table 11. Effect of Chloroform on Vinyl Chloride ................................................................................... 21
Table 12. Effect of Vinyl Chloride on Chloroform .................................................................................... 22
Table 13. Effect of 1,1-Dichloroethylene on Trichloroethylene ................................................................. 23
Table 14. Effect of Trichloroethylene on 1,1-Dichloroethylene ................................................................. 24
Table 15. Effect of 1,1-Dichloroethylene on Vinyl Chloride ................................................................. 25
Table 16. Effect of Vinyl Chloride on 1,1-Dichloroethylene .................................................................... 26
Table 17. Effect of Trichloroethylene on Vinyl Chloride .......................................................................... 27
Table 18. Effect of Vinyl Chloride on Trichloroethylene ........................................................................ 28
Table 19. PBPK models’ predictions of interaction thresholds ................................................................. 29
Table 20. Minimal Risk Levels (MRLs) for the Chemicals of Concern ..................................................... 30
Table 21. MRLs and TTDs for Intermediate Inhalation Exposure to Chemicals of Concern .................. 32
Table 22. MRLs and TTDs for Chronic Inhalation Exposure to Chemicals of Concern ............................. 33
Table 23. MRLs and TTDs for Intermediate Oral Exposure to Chemicals of Concern ............................. 33
Table 24. MRLs and TTDs for Chronic Oral Exposure to Chemicals of Concern ...................................... 34
Table 25. Matrix of BINWOE Determinations for Simultaneous Exposure to High Levels of Chemicals of Concern......................................................................................................................... 36

***DRAFT—DO NOT CITE OR QUOTE—***
**LIST OF ACRONYMS, ABBREVIATIONS, AND SYMBOLS**

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AKT</td>
<td>α-ketoglutarate transaminase</td>
<td>LEC</td>
<td>lower 95% confidence limit</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine aminotransaminase</td>
<td>LOAEL</td>
<td>lowest-observed-adverse-effect level</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate aminotransferase</td>
<td>LSE</td>
<td>Levels of Significant Exposure</td>
</tr>
<tr>
<td>ATSDR</td>
<td>Agency for Toxic Substances and Disease Registry</td>
<td>mg</td>
<td>milligram</td>
</tr>
<tr>
<td>AUC</td>
<td>area under the curve</td>
<td>MRL</td>
<td>Minimal Risk Level</td>
</tr>
<tr>
<td>BINWEO</td>
<td>binary weight-of-evidence</td>
<td>NOAEL</td>
<td>no-observed-adverse-effect level</td>
</tr>
<tr>
<td>BMDS</td>
<td>Benchmark Dose Software</td>
<td>NTP</td>
<td>National Toxicology Program</td>
</tr>
<tr>
<td>CERCLA</td>
<td>Comprehensive Environmental Response, Compensation, and Recovery Act</td>
<td>ppm</td>
<td>parts per million</td>
</tr>
<tr>
<td>CHCl₃</td>
<td>chloroform</td>
<td>PVC</td>
<td>polyvinylchloride</td>
</tr>
<tr>
<td>COCl₂</td>
<td>phosgene</td>
<td>RFCD</td>
<td>reference concentration</td>
</tr>
<tr>
<td>DCE</td>
<td>1,1-dichloroethylene</td>
<td>RfD</td>
<td>reference dose</td>
</tr>
<tr>
<td>DCVC</td>
<td>S-(1,2-dichlorovinyl)-L-cysteine</td>
<td>RNA</td>
<td>ribonucleic acid</td>
</tr>
<tr>
<td>DCVG</td>
<td>S-(1,2-dichlorovinyl)glutathione</td>
<td>SDH</td>
<td>sorbitol dehydrogenase</td>
</tr>
<tr>
<td>DNA</td>
<td>deoxyribonucleic acid</td>
<td>SGOT</td>
<td>serum glutamic oxaloacetic transaminase</td>
</tr>
<tr>
<td>DT</td>
<td>Division of Toxicology</td>
<td>SGPT</td>
<td>serum glutamic pyruvic transaminase</td>
</tr>
<tr>
<td>EPA</td>
<td>Environmental Protection Agency</td>
<td>TCE</td>
<td>trichloroethylene</td>
</tr>
<tr>
<td>F₁</td>
<td>first-filial generation</td>
<td>TTD</td>
<td>target-organ toxicity dose</td>
</tr>
<tr>
<td>GGT</td>
<td>gamma glutamyl transpeptidase</td>
<td>TWA</td>
<td>time-weighted average</td>
</tr>
<tr>
<td>GOT</td>
<td>glutamic oxaloacetic transaminase</td>
<td>µg</td>
<td>microgram</td>
</tr>
<tr>
<td>GSH</td>
<td>glutathione</td>
<td>U.S.</td>
<td>United States</td>
</tr>
<tr>
<td>HEC</td>
<td>human equivalent concentration</td>
<td>VC</td>
<td>vinyl chloride</td>
</tr>
<tr>
<td>HI</td>
<td>hazard index</td>
<td>WOE</td>
<td>weight-of-evidence</td>
</tr>
<tr>
<td>IARC</td>
<td>International Agency for Research on Cancer</td>
<td>&gt;</td>
<td>greater than</td>
</tr>
<tr>
<td>IgG</td>
<td>immunoglobulin G</td>
<td>≥</td>
<td>greater than or equal to</td>
</tr>
<tr>
<td>Ip</td>
<td>intraperitoneal</td>
<td>=</td>
<td>equal to</td>
</tr>
<tr>
<td>IRIS</td>
<td>Integrated Risk Information System</td>
<td>&gt;</td>
<td>greater than or equal to</td>
</tr>
<tr>
<td>kg</td>
<td>kilogram</td>
<td>≤</td>
<td>less than or equal to</td>
</tr>
<tr>
<td>L</td>
<td>liter</td>
<td>&lt;</td>
<td>less than</td>
</tr>
<tr>
<td>LDH</td>
<td>lactate dehydrogenase</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

***DRAFT—DO NOT CITE OR QUOTE***